Krystal Biotech is trading 5.7% down at $320.00 following a mixed second-quarter 2026 earnings report that saw revenue fall short of analyst estimates.
- Revenue from flagship product VYJUVEK grew 24% year-over-year to $119.2 million but missed consensus targets, while EPS of $1.79 beat expectations.
- Investors are reassessing the stock following a strategic pivot toward a multi-product pipeline, potentially triggering profit-taking after a strong year-to-date run.
- The decline appears company-specific as broader market indices are currently trading higher.